Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 17, 2005. The report primarily details changes in directors' interests in ordinary shares and a share repurchase transaction authorized by shareholders at the Annual General Meeting on May 17, 2004.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes regarding share ownership.
- Share Repurchase Price: 1,346.88 pence per share.
- Shares Purchased: 500,000 ordinary shares.
- Treasury Shares Held: 90,083,000 (post-transaction).
- Shares in Issue: 5,852,296,022 (excluding treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback program and the transfer of shares from an employee trust to plan participants.
- Share Buyback: On May 17, 2005, the company purchased 500,000 shares to be held in treasury.
- Employee Trust Transfer: On May 16, 2005, the GlaxoSmithKline Employee Trust transferred 5,267 ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural disclosure regarding equity transactions.
Key Facts for Investor Verification
- Verify the total cost of the 500,000 share repurchase against the stated price of 1,346.88 pence per share.
- Confirm the updated total share count (5,852,296,022 in issue) against subsequent filings to ensure accuracy.
- Review the impact of the 90,083,000 treasury shares on earnings per share (EPS) calculations in future reports.
- Note that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold indirect interests in the GSK Trust shares.